Kalytera Therapeutics Inc. (TSX: V.KALY, OTCQB: KALTF, Forum) reported positive interim data on Thursday from its ongoing Phase 2 clinical study evaluating cannabidiol (CBD) for the prevention of acute graft versus host disease following bone marrow transplant.
More information can be foundhere.
The Companyalso made news this weekwhen it entered into agreements to sell an aggregate 11,532,000 of its common shares and 11,532,000 common share purchase warrants for aggregate gross proceeds of $605,430 (CAD).
FULL DISCLOSURE: Kalytera Therapeutics Inc. is a client of Stockhouse Publishing.